newsfilter
← Latest News
GlobeNewswire·

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

  • Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) announced that CEO Jayson Rieger, PhD, MBA, will present at the H.C. Wainwright 28th Annual Global Investment Conference.
  • The conference presentation is scheduled for Monday, September 14, 2026, at 1:00pm ET in New York, NY.
  • A live webcast will be accessible via a provided link or the Investors/Presentations & Events section of Verrica's website at www.verrica.com.
  • A replay of the webcast will be posted shortly after the event \& available for 90 days.
  • Verrica develops medications for dermatological diseases, including skin cancers.
  • YCANTH® (VP-102) is the first FDA-approved healthcare professional-administered treatment for molluscum contagiosum in patients aged two years & older.
  • YCANTH® (VP-102) is also in development to treat common warts.
  • Verrica has a worldwide license agreement with Lytix Biopharma ASA to develop \& commercialize VP-315 (ruxotemitide) for non-melanoma skin cancers.